Mymetics’ vision is to become the market leader in the development of new generation mucosal and virosomes based vaccines. The Company develops preventative vaccines that generate an efficient mucosal protection through mucosal antibodies as first line of defense, while blood antibodies would act synergistically, as second line of defense.

To date, the focus has been on achieving very favorable results from the development of a core vaccine pipeline of HIV-1 and Malaria, while securing the IP and know-how for the virosome platform and the mucosal based approach.

Through the recent acquisition of Mymetics BV (formerly known as Virosome Biologicals B.V.), the Company has further secured rights and access to know-how of key virosome technologies and added three additional vaccines: Respiratory Syncytial Virus (RSV), Herpes Simplex Virus (HSV) and Influenza (out-licensed).
By using a lean and flexible operational platform and contracting best-in-class partners, Mymetics has avoided the upfront cost of in-house resources and gains access to the best existing know-how. This has maximized the return on development and research.

In summary, the strategy for Mymetics is to extend the application of its key scientific approaches to new vaccines by:

• Leveraging the effective and safe virosome vaccine delivery platform and know-how
• Exploiting the results and knowledge of mucosal protection based vaccines
• Advancement of existing vaccine candidates up to maximum Phase II
• Maintenance of a comprehensive IP portfolio
• Flexible cost model based on a combination of in-house expertise and best-in-class
outsourcing
• Strategic partnerships with leading pharmaceuticals.